Literature DB >> 34668421

Separating the contributions of SLC26A9 and CFTR to anion secretion in primary human bronchial epithelia.

Mads B Larsen1, Jeannie J Choi2, Xiaohui Wang2, Michael M Myerburg3, Raymond A Frizzell1,2, Carol A Bertrand2.   

Abstract

Aberrant anion secretion across the bronchial epithelium is associated with airway disease, most notably in cystic fibrosis. Although the cystic fibrosis transmembrane conductance regulator (CFTR) is recognized as the primary source of airway anion secretion, alternative anion transport mechanisms play a contributing role. An alternative anion transporter of growing interest is SLC26A9, a constitutively active chloride channel that has been shown to interact with CFTR and may also contribute to bicarbonate secretion. Interest in SLC26A9 has been fueled by genome-wide association studies that suggest it is a significant modifier of CF disease severity. Despite this growing evidence that SLC26A9 plays an important role in the airway, its presence and function in bronchial epithelia remain poorly understood, in part, because its activity is difficult to separate from the activity of CFTR. Here, we present results using primary human bronchial epithelia (HBE) from multiple patient sources to confirm that SLC26A9 mRNA is present in HBE and that its constitutive channel activity is unaffected by knockdown of CFTR. Furthermore, SLC26A9 and CFTR show differential responses to common inhibitors of anion secretion. Finally, we assess the impact of bicarbonate on the activity of SLC26A9 and CFTR. These results confirm that SLC26A9 is the primary source of constitutive anion secretion across HBE, and should inform future studies focused on activation of SLC26A9 as an alternative anion channel in CF. These results should provide a strong foundation to investigate how single-nucleotide polymorphisms in SLC26A9 modulate airway disease.

Entities:  

Keywords:  CF disease modifier; chloride channels; cystic fibrosis; electrophysiology; primary bronchial epithelia

Mesh:

Substances:

Year:  2021        PMID: 34668421      PMCID: PMC8715023          DOI: 10.1152/ajplung.00563.2020

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  31 in total

Review 1.  The emerging role of PDZ adapter proteins for regulation of intestinal ion transport.

Authors:  G Lamprecht; U Seidler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-06-22       Impact factor: 4.052

2.  The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9.

Authors:  Carol A Bertrand; Shalini Mitra; Sanjay K Mishra; Xiaohui Wang; Yu Zhao; Joseph M Pilewski; Dean R Madden; Raymond A Frizzell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-03-30       Impact factor: 5.464

Review 3.  Airway hydration and COPD.

Authors:  Arunava Ghosh; R C Boucher; Robert Tarran
Journal:  Cell Mol Life Sci       Date:  2015-06-12       Impact factor: 9.261

4.  The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR.

Authors:  Yukiko Sato; David Y Thomas; John W Hanrahan
Journal:  J Biol Chem       Date:  2019-10-23       Impact factor: 5.157

5.  Characterization of SLC26A9, facilitation of Cl(-) transport by bicarbonate.

Authors:  Celine Loriol; Sandrine Dulong; Martine Avella; Nicole Gabillat; Kim Boulukos; Franck Borgese; Jordi Ehrenfeld
Journal:  Cell Physiol Biochem       Date:  2008-07-25

6.  Evidence for direct CFTR inhibition by CFTR(inh)-172 based on Arg347 mutagenesis.

Authors:  Emanuela Caci; Antonella Caputo; Alexandre Hinzpeter; Nicole Arous; Pascale Fanen; Nitin Sonawane; A S Verkman; Roberto Ravazzolo; Olga Zegarra-Moran; Luis J V Galietta
Journal:  Biochem J       Date:  2008-07-01       Impact factor: 3.857

Review 7.  Functional interaction of the cystic fibrosis transmembrane conductance regulator with members of the SLC26 family of anion transporters (SLC26A8 and SLC26A9): physiological and pathophysiological relevance.

Authors:  Elma El Khouri; Aminata Touré
Journal:  Int J Biochem Cell Biol       Date:  2014-02-14       Impact factor: 5.085

8.  Cardiac ion channel current modulation by the CFTR inhibitor GlyH-101.

Authors:  Palash P Barman; Stéphanie C M Choisy; Hanne C Gadeberg; Jules C Hancox; Andrew F James
Journal:  Biochem Biophys Res Commun       Date:  2011-03-31       Impact factor: 3.575

9.  SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia.

Authors:  Carol A Bertrand; Ruilin Zhang; Joseph M Pilewski; Raymond A Frizzell
Journal:  J Gen Physiol       Date:  2009-03-16       Impact factor: 4.086

10.  Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy.

Authors:  Chatchai Muanprasat; N D Sonawane; Danieli Salinas; Alessandro Taddei; Luis J V Galietta; A S Verkman
Journal:  J Gen Physiol       Date:  2004-08       Impact factor: 4.086

View more
  2 in total

Review 1.  SLC26A9 as a Potential Modifier and Therapeutic Target in Cystic Fibrosis Lung Disease.

Authors:  Giulia Gorrieri; Federico Zara; Paolo Scudieri
Journal:  Biomolecules       Date:  2022-01-25

2.  Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease.

Authors:  Jiafen Gong; Gengming He; Cheng Wang; Claire Bartlett; Naim Panjwani; Scott Mastromatteo; Fan Lin; Katherine Keenan; Julie Avolio; Anat Halevy; Michelle Shaw; Mohsen Esmaeili; Guillaume Côté-Maurais; Damien Adam; Stéphanie Bégin; Candice Bjornson; Mark Chilvers; Joe Reisman; April Price; Michael Parkins; Richard van Wylick; Yves Berthiaume; Lara Bilodeau; Dimas Mateos-Corral; Daniel Hughes; Mary J Smith; Nancy Morrison; Janna Brusky; Elizabeth Tullis; Anne L Stephenson; Bradley S Quon; Pearce Wilcox; Winnie M Leung; Melinda Solomon; Lei Sun; Emmanuelle Brochiero; Theo J Moraes; Tanja Gonska; Felix Ratjen; Johanna M Rommens; Lisa J Strug
Journal:  NPJ Genom Med       Date:  2022-04-08       Impact factor: 8.617

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.